Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Detection of DNA in forensic samples is improved by Pressure BioSciences, Inc. No doubt Chinese wanted and can afford it. They got the money over there!
12 countries, lots of things in the making. people dont yet realize otherwise theyd be all here and not chasing pinksheet stocks, basically empty shells theyre trading. PBIO is true investment!
yes, 0.5 first. and then 0.7 Sounds good!
PBIOis a research products and services provider for the life science industry.
We are impressed and optimistic about the Company s novel, enabling platform technology pressure cycling technology (PCT) which has
competitive advantages over existing technologies in the sample preparation market. PCT is increasingly gaining recognition by research labs. The Company just reported record PCT product sales in 3Q12 and we expect continued growth in 4Q12 and beyond.
source: Zacks.com
Good Morning PBIO looking good, green close after PR. Lets continue this trend, shall we?
news today is reassuring, glad im in it before others will get the idea too. lol
news today is reassuring, glad im in it before others will get the idea too. lol
HIDDEN GEM! PBIO$$$
As PR states revenue will enter into high growth in 2013 and beyond.
this is what we need folks - expansion capital!!!
News: Pressure BioSciences (PBIO), High Growth Expected for 2013 and Beyond
Another Strong Quarter of Product Sales is Expected
After booking record sales of PCT products in third quarter of 2012, we are expecting another strong quarter of product sales for fourth quarter of 2012.
We estimate product sales of $0.32 million for the fourth quarter of 2012, a 79% increase compared to $0.18 million product sales of 4Q11. These product sales include PCT equipment and consumables.
Grant revenue is expected to be $0.10 million for 4Q12, compared to $0.16 million for 4Q11.
Total revenue based on our estimate will be $0.42 million for the fourth quarter of 2012, compared to $0.34 million for the fourth quarter of 2011, an increase of 25%.
Gross margin for product sales is estimated to be 65.6% for the 4Q12, compared to 48.5% for the 4Q11, a 35% improvement.
Operating loss is expected to be $0.7 million for the 4Q12, compared to operating loss of $0.9 million for 4Q11, a 22% improvement.
We estimate that net loss will be $0.9 million or $0.08 per share, compared to net loss of $2.0 million or $0.30 per share.
Based on the improvements of financial results for the last three quarters of 2012, and the aggressive commercialization strategy the Company has implemented in 2012, we expect revenue will enter into high growth in 2013 and beyond. From 2012 to 2015, net product sales will grow at amazing 118% compound annual growth rate (CAGR). PBIO will become profitable in fiscal 2015 with EPS of $0.06 based on total revenue of $11 million.
We think the share price of PBIO is undervalued. At this time, the downside risk is low while upside potential is high for the Company.
Leadership Strengthened by Appointing New Chief Financial Officer
On December 5, 2012, Pressure BioSciences, Inc. (OTC Markets:PBIO) announced that Mr. Conrad F. Mir has joined the Company as its chief financial officer, effective immediately.
Mr. Mir has over twenty years experience in investment banking, financial structuring, and corporate reengineering. He has served in various executive management roles and on the Board of Directors of several companies in the biotechnology industry. Most recently, Mr. Mir was chairman and CEO of Genetic Immunity, Inc. (:GI), a plasmid, DNA company in the HIV space. Prior to GI, Mr. Mir served as executive director of Advaxis, Inc., a vaccine company. During his tenure at GI and Advaxis, Mr. Mir was responsible for raising nearly $40 million in growth capital and broadening corporate reach to new investors and current shareholders.
Prior to GI and Advaxis, Mr. Mir worked for several investment banks including Sanford C. Bernstein, First Liberty Investment Group, and Nomura Securities International. He holds a BA/BS in Economics and English with special concentrations in Mathematics and Physics from New York University.
PBIO recently announced record PCT product sales for the third quarter of 2012, and we expect another strong quarter of product sales for the 4Q12. The Company has implemented aggressive commercialization strategy in 2012 to accelerate the revenue growth of its patented PCT products and services which included, among other things, an increase in international sales and distribution coverage from three to over twenty countries. But PBIO needs to properly finance this initiative. This is currently the biggest concern.
We believe the strong investment banking background of Mr. Mir will help PBIO raise new capital to fund its operations. It is also one of Conrad’s best strengths. He has proven over the past few years that he has the ability to raise significant funds for small, developing companies in a smart and timely way.
Please visit SCR.Zacks.com for additional information on our research and coverage universe, and Subscribe to receive our articles and reports emailed directly to you each morning.
Read the Full Research Report on PBIO
Zacks Investment Research
http://finance.yahoo.com/news/pressure-biosciences-pbio-high-growth-152335014.html
Pressure BioSciences, groups are moving in this stock rocks!
thats right, will be making a good chunk of cash here!
counter-bioterror applications will be a break through for sure, Uplisting immediately after contract signed!!!
Early bird gets the worm, anything under .05 is very safe investment folks, $1+ expected within a month!
Pressure BioSciences will get known in March PERIOD
Company is solid, huge upside,just need a few PR so peeps can see it and join the party!
I agree Edou this month might just be what we are waiting for, March should be busy here,
glty
PR next week would be perfect - cant wait!
March should be a fun month , PBIO$
Pressure BioSciences is a perfect investment at this level, company is ready to get known internationally. Just a matter of time here, imho
Just need PR and i alert my boyzzz, easy money here, imo
thanks checking pressurebiosciences site now, doing my DD here.
any thoughts?
I agree PBIO is ready to shine.. glty
go PBIO!
$1 is very realistic here based on the charts, cant wait!
undervalued no doubt, thanks for link edou777
$1 coming is what i heard March should be fun
still in it? thinking to get back in.
i heard some nice rumors! Radar PBIO
im a bagholder here so far, thanks FB! lol
go SNTL, i see strong bid support, you gotta be in it to Win! weee
Low Float! SNTL!!
sntl, stronger than you think! buys will keep coming in. Announcements will be huge!
SNTL News will be huge! $SNTL
UPLIst to the OTCBB , i see $1 coming!
good thinking Carter, each door opens another. pps drops smart people dont panic sell but buy!
GM, this morning was a good example that nothing can stop SNTL,, up we go!
lets see strong close today, nice and greeen